Vanguard Portfolio Management’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
Other funds holding PRME
AI
AIM
CC
WP
Vanguard Portfolio Management's PRME Position: Q2 2026 in Review
Vanguard Portfolio Management increased its Prime Medicine (PRME) stake by 12% in Q2 2026, buying an estimated $331K and bringing the position to 961,826 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2540.
Vanguard Portfolio Management first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.
- Vanguard Portfolio Management held 961,826 shares of Prime Medicine worth $3.55M as of Q2 2026.
- Vanguard Portfolio Management bought 99,622 Prime Medicine shares in Q2 2026, an estimated $331K.
- Prime Medicine made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2540 holding.
- Vanguard Portfolio Management first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
- 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.
Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.